drugset / Trial / NCT04297254
A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety of lenvatinib in HCC.
Timeline
- Start
- 2021-02-04
- Primary completion
- 2023-07-31
- Completion
- 2023-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |